Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a leading pharmaceutical company based in China, has announced that it has obtained marketing approval from the National Medical Products Administration (NMPA) for its generic version of GlaxoSmithKline’s (GSK) Seretide (salmeterol, fluticasone). This compound inhalable preparation is now approved for use as a regular treatment for reversible obstructive airway diseases, including asthma in both adults and children.
Seretide, the pioneering product of its kind globally, achieved sales of RMB 783 million in China in 2023. Joincare’s launch marks the introduction of the first generic version of this medication in the Chinese market.- Flcube.com
